These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND SDHB, PGL4, 6390, ENSG00000117118, SDH1, SDHIP, SDH, IP
387 results:

  • 1. Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells.
    Zeng C; Nie D; Wang X; Zhong S; Zeng X; Liu X; Qiu K; Peng X; Zhang W; Chen S; Zha X; Chen C; Chen Z; Wang W; Li Y
    Mol Cancer; 2024 Oct; 23(1):240. PubMed ID: 39465372
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. E41K mutation activates Bruton's tyrosine kinase by stabilizing an inositol hexakisphosphate-dependent invisible dimer.
    Chowdhury S; Chakraborty MP; Roy S; Dey BP; Gangopadhyay K; Das R
    J Biol Chem; 2024 Aug; 300(8):107535. PubMed ID: 38971313
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway.
    Wang H; Wang L; Luan H; Xiao J; Zhao Z; Yu P; Deng M; Liu Y; Ji S; Ma J; Zhou Y; Zhang J; Meng X; Zhang J; Zhao X; Li C; Li F; Wang D; Wei S; Hui L; Nie S; Jin C; An Z; Zhang N; Wang Y; Zhang CC; Li Z
    J Exp Clin Cancer Res; 2024 Jul; 43(1):183. PubMed ID: 38951916
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia.
    Zheng R; Wei W; Liu S; Zeng D; Yang Z; Tang J; Tan J; Huang Z; Gao M
    Cell Commun Signal; 2024 Jun; 22(1):314. PubMed ID: 38849885
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2.
    Wen D; Xiao H; Gao Y; Zeng H; Deng J
    Mol Cancer; 2024 May; 23(1):116. PubMed ID: 38822351
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations.
    Tawfik HO; Mousa MHA; Zaky MY; El-Dessouki AM; Sharaky M; Abdullah O; El-Hamamsy MH; Al-Karmalawy AA
    Bioorg Chem; 2024 Aug; 149():107483. PubMed ID: 38805913
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Daunorubicin induces GLI1‑dependent apoptosis in colorectal cancer cell lines.
    Kim BR; Kim DY; Tran NL; Kim BG; Lee SI; Kang SH; Min BY; Hur W; Oh SC
    Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757343
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. CHMP5 attenuates osteoarthritis via inhibiting chondrocyte apoptosis and extracellular matrix degradation: involvement of NF-κB pathway.
    Gao W; Liu R; Huang K; Fu W; Wang A; Du G; Tang H; Yin L; Yin ZS
    Mol Med; 2024 Apr; 30(1):55. PubMed ID: 38664616
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. m
    Zhao Y; Zhou Y; Qian Y; Wei W; Lin X; Mao S; Sun J; Jin J
    Clin Transl Med; 2024 Apr; 14(4):e1628. PubMed ID: 38572589
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. LRRC1 knockdown downregulates MACF1 to inhibit the malignant progression of acute myeloid leukemia by inactivating β-catenin/c-Myc signaling.
    Wang Y; Tong H; Wang J; Hu L; Huang Z
    J Mol Histol; 2024 Feb; 55(1):37-50. PubMed ID: 38165568
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. FAT1 inhibits AML autophagy and proliferation via downregulating ATG4B expression.
    Zhang N; Shen MY; Meng QL; Sun HP; Fan FY; Yi H; Yang YJ
    Biochim Biophys Acta Gen Subj; 2024 Jan; 1868(1):130519. PubMed ID: 37952564
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MLL1 inhibits the neurogenic potential of SCAPs by interacting with WDR5 and repressing HES1.
    Zhang C; Ye W; Zhao M; Long L; Xia D; Fan Z
    Int J Oral Sci; 2023 Oct; 15(1):48. PubMed ID: 37852994
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Targeting SDCBP2 in acute myeloid leukemia.
    Du Y; Li LL; Chen F; Du Y
    Cell Signal; 2023 Dec; 112():110889. PubMed ID: 37714445
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1.
    Lu L; Wang J; Fang F; Guo A; Jiang S; Tao Y; Zhang Y; Li Y; Zhang K; Zhang Z; Zhuo R; Chu X; Li X; Tian Y; Ma L; Sang X; Chen Y; Yu J; Yang Y; Cao H; Gao J; Lu J; Hu S; Pan J; He H
    Cell Death Dis; 2023 Aug; 14(8):518. PubMed ID: 37573405
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Nrh L11R single nucleotide polymorphism, a new prediction biomarker in breast cancer, impacts endoplasmic reticulum-dependent Ca
    Duong MQ; Gadet R; Treilleux I; Borel S; Nougarède A; Marcillat O; Gonzalo P; Mikaelian I; Popgeorgiev N; Rimokh R; Gillet G
    Cell Death Dis; 2023 Jul; 14(6):392. PubMed ID: 37391438
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Muramyl dipeptide CD10 monoclonal antibody immunoconjugates inhibited acute leukemia in nude mice.
    Wang Y; Jin X; Sun Y; Zhao Y; Qu Z; Wang L; Sun L
    Biosci Rep; 2023 Apr; 43(4):. PubMed ID: 37039042
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.
    Moore JE; Bloom PC; Chu CC; Bruno JE; Herne CA; Baran AM; Quataert SA; Mosmann TR; Taylor RP; Wallace DS; Elliott MR; Barr PM; Zent CS
    Leuk Res; 2023 Jun; 129():107072. PubMed ID: 37003030
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Comparative treatment costs of risk-stratified therapy for childhood acute lymphoblastic leukemia in India.
    Mungle T; Das N; Pal S; Gogoi MP; Das P; Ghara N; Ghosh D; Arora RS; Bhakta N; Saha V; Krishnan S
    Cancer Med; 2023 Feb; 12(3):3499-3508. PubMed ID: 36812120
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Selenylated Imidazo[1,2
    Burkner GT; Dias DA; Souza KFS; Araújo AJP; Basilio DCLS; Jacobsen FT; Moraes ACR; Silva-Filho SE; Cavalcante MFO; Moraes CAO; Saba S; Macedo MLR; Paredes-Gamero EJ; Rafique J; Parisotto EB
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677949
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
    Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
    Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 20.